News
Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)
Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicity
Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium
Event brings together leading academics, industry representatives and investors to share progress and discuss future directions in dark genome research and the development of novel therapeutics
All News
Browse our full news archives
Publications
Scientific posters highlighting our Dark Antigens as novel immunotherapy targets for solid tumors
A short selection of the growing scientific literature that inspires us to shine a light on genomic dark matter
Upcoming & Recent Events
Discover the events that the Enara Bio team are attending